The Business Development Bank of Canada (BDC) has announced its strategic return to direct life sciences investing with a new $150-million venture fund. Managed by BDC Capital, this fund will target early-stage companies in therapeutics and medical technology to address a persistent capital gap. Veteran biotech executive Parimal Nathwani has been appointed as the fund's managing partner to spearhead this initiative.
Addressing a Critical Funding Gap
The fund will focus on providing patient capital to companies at the seed and Series A stages, aiming to support 10 to 15 ventures. Initial investments will range from $1 million to $3 million at the seed stage, with larger cheques of $5 million to $8 million for Series A rounds. This strategy is designed to help promising companies navigate the crucial early phases of development and commercialization.
This initiative comes as the Canadian life sciences sector faces a significant downturn in funding, with investment hitting a multi-year low. Despite demonstrating strong long-term venture capital returns, the sector struggles with a lack of specialized, early-stage investors. The new fund aims to fill this void, providing essential capital for ventures with intensive and lengthy development cycles.
Strategic Re-entry and Leadership
BDC's launch marks a significant pivot after it spun off its previous health-care fund into the private firm Amplitude Ventures in 2019. The bank's leadership has since acknowledged that this exit from direct investment may have been premature given the sector's growing needs. This new fund represents a deliberate effort to re-engage and provide foundational support to a critical area of innovation.
Leading the fund is Parimal Nathwani, who brings over two decades of industry experience to the role. As the former head of the Toronto Innovation Acceleration Partners (TIAP), he has a proven track record of building and scaling biotechnology companies. His deep expertise in commercialization and scientific validation is considered a vital asset for guiding the fund's portfolio companies.
Fostering Canadian Innovation and Sovereignty
The fund's mission extends beyond financial returns, aiming to bolster Canada's economic sovereignty and national security. By financing domestic innovation, BDC intends to help retain top scientific talent and ensure that crucial health solutions are developed within the country. This investment reinforces the life sciences sector's role as a major engine of Canada's economy, contributing over $18 billion annually.
As Canada's development bank, BDC Capital plans to lead investment rounds, thereby attracting both domestic and international co-investors to the table. This approach is intended to de-risk opportunities for private capital and build a more robust financing ecosystem for the entire sector. The long-term vision includes launching subsequent funds to provide sustained support for Canadian life sciences ventures in the future.
Ultimately, the launch of the $150-million Life Sciences Venture Fund is a decisive step by BDC to champion a vital Canadian industry. With strategic leadership and a clear mandate, the fund is poised to transform promising domestic research into globally competitive enterprises. This renewed commitment signals a brighter future for early-stage life sciences companies across the country.